AIM at Melanoma

AIM at Melanoma is globally engaged and locally invested in advancing the battle against melanoma through innovative research, legislative reform, education, and patient and caregiver support. AIM's global initiatives are fundamentally changing the face and future of research to advance discovery of the CURE for melanoma. AIM arms researchers with cutting-edge tools and resources needed to make game-changing discoveries. AIM provides comprehensive easy-to-access melanoma information and supports patients, survivors, and caregivers. AIM represents the voice of the melanoma community in promoting legislative and regulatory changes, here and around the world. AIM drives awareness and provides opportunities for the community to get involved and make a difference. AIM's founders lost their loved ones to melanoma - Charlie Guild and Jim Schlipmann - so finding the CURE is personal.